AAP
INO icon

Arax Advisory Partners’s Inovio Pharmaceuticals INO Stock Holding History

Arax Advisory Partners’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113 Buy
+103
New +$122 ﹤0.01% 5131
2026
Q1 		– Sell
-103
Closed -$179 – 4065
2025
Q4 		$179 Hold
103
– – ﹤0.01% 3740
2025
Q3 		$241 Buy
+103
New +$197 ﹤0.01% 3434

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arax Advisory Partners's INO Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Inovio Pharmaceuticals (INO) in Q2 2026: 103 shares worth $113. The stake represents ﹤0.01% of the portfolio and ranks #5131 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in INO as recently as Q4 2025.

Arax Advisory Partners first reported a position in INO in Q3 2025 and has held it in 3 quarters since. The position peaked at $241 in Q3 2025. 102 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Arax Advisory Partners held 103 shares of Inovio Pharmaceuticals worth $113 as of Q2 2026.
  • Inovio Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5131 holding.
  • Arax Advisory Partners first reported a position in Inovio Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Inovio Pharmaceuticals position peaked at $241 in Q3 2025.
  • 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.